Gene Therapy
-
Gene editing
Beam’s base editing therapy for sickle cell hits goal in pivotal trial
The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.
By Jonathan Gardner • Nov. 10, 2026 -
Novartis reveals cancer cases possibly linked to gene therapy Zolgensma
The FDA is now investigating the risk of malignancy associated with Zolgensma and is “evaluating whether regulatory action is appropriate.”
By Jonathan Gardner • Updated Nov. 9, 2026 -
Explore the Trendline➔
Getty Images
TrendlineGene Therapy
Rapid scientific advances have put the gene therapy field at the forefront of biomedical research. But, as recent setbacks have shown, researchers and drugmakers still face major challenges.
By BioPharma Dive staff -
Immune reset
Artiva to quit autoimmune cell therapy work, cut staff after patient deaths
The disclosure makes Artiva the third company to recently report fatal events in an autoimmune cell therapy trial, following announcements from Novartis and Bristol Myers Squibb.
By Gwendolyn Wu • Oct. 27, 2026 -
Merck KGaA bets on RNAi with $1.3B Silence buyout
The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.
By Jonathan Gardner • Oct. 19, 2026 -
Biogen-backed Estuary nabs $93M for kidney disease gene therapy
The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as "ADPKD."
By Jacob Bell • Oct. 16, 2026 -
Belgian startup revives Galapagos CAR-T research
Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.
By Jonathan Gardner • Oct. 15, 2026 -
IPO window
Parkinson’s cell therapy developer files to go public
Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a patient's own cells into dopamine-producing neurons.
By Jacob Bell • Oct. 12, 2026 -
del Aguila III, Ernesto. (2018). "CRISPR Cas9" [Illustration]. Retrieved from Flickr.
Gene editingCaribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate
Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure funding to support the effort and will now pursue “strategic alternatives” instead.
By Kristin Jensen • Oct. 7, 2026 -
Gene editing
Beam sues 2 biotechs, alleging theft of base editing trade secrets
Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges.
By Gwendolyn Wu • Sept. 29, 2026 -
UniQure tumbles with latest data for Huntington’s gene therapy
Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting a potential approval of "AMT-130."
By Jacob Bell • Sept. 29, 2026 -
Roche, Ionis RNA drug scores in kidney disease study
The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.
By Jonathan Gardner • Sept. 23, 2026 -
Beacon eye gene therapy hits mark in late-stage study
Beacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially blinding condition, met its main goal in a pivotal trial.
By Gwendolyn Wu • Sept. 21, 2026 -
News roundup
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.
By BioPharma Dive staff • Sept. 18, 2026 -
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.
By Jonathan Gardner • Sept. 14, 2026 -
Vaccines
mRNA cancer vaccines’ biggest barriers to market
Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
By Alexandra Pecci • Sept. 11, 2026 -
BrainChild hauls in $116M to make cell therapies for childhood brain cancers
Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly pediatric cancer into mid-stage testing.
By Gwendolyn Wu • Sept. 8, 2026 -
The hidden scale-out problem behind CAR-T’s growth
CAR-T’s commercial challenge is making thousands of patient-specific manufacturing runs behave like one reliable system. "In vivo" production techniques could be one solution.
By Sy Mukherjee • Sept. 3, 2026 -
Immune reset
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.
By Jonathan Gardner • Sept. 2, 2026 -
UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapy
The company is now hoping for an affirmative answer on its application after an unusually turbulent year dealing with U.S. regulators.
By Kristin Jensen • Sept. 2, 2026 -
Immune reset
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
The deaths of three study participants led Novartis to halt development of rap-cel in multiple indications, while “transient” side effects pushed Bristol Myers to voluntarily pause its zola-cel program.
By Gwendolyn Wu • Updated Sept. 1, 2026 -
Safety concerns spur FDA to again halt testing of Regenxbio gene therapy
Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program’s second clinical hold this year.
By Delilah Alvarado • Aug. 24, 2026 -
Ultragenyx, after setbacks, nabs first gene therapy approval
The clearance of Genglycos for a rare glycogen storage disease gives Ultragenyx a sellable voucher and momentum ahead of an eagerly anticipated study readout.
By Kristin Jensen • Aug. 20, 2026 -
PTC takes a chance on Sangamo’s Fabry disease gene therapy
Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.
By Kristin Jensen • Aug. 13, 2026 -
Q&A // Gene editing
Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
By Gwendolyn Wu • Aug. 10, 2026 -
Vaccines
FDA approves Moderna’s mRNA flu vaccine
The clearance paves the way for the first preventive flu shot based on mRNA technology and completes a dramatic regulatory turnaround.
By Delilah Alvarado • Aug. 6, 2026